{"organizations": [], "uuid": "23f5e5af90990d9d5c43e4c2936b293465b5dcdc", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/finance/markets", "section_title": "Markets &amp; Finance News | Reuters.com", "url": "https://www.reuters.com/article/brief-kempharm-announces-fda-approval-of/brief-kempharm-announces-fda-approval-of-apadaz-idUSB8N1FK03A", "country": "US", "domain_rank": 408, "title": "BRIEF-Kempharm Announces FDA Approval Of Apadaz", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.997, "site_type": "news", "published": "2018-02-24T03:05:00.000+02:00", "replies_count": 0, "uuid": "23f5e5af90990d9d5c43e4c2936b293465b5dcdc"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-kempharm-announces-fda-approval-of/brief-kempharm-announces-fda-approval-of-apadaz-idUSB8N1FK03A", "ord_in_thread": 0, "title": "BRIEF-Kempharm Announces FDA Approval Of Apadaz", "locations": [], "entities": {"persons": [{"name": "kempharm", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "kempharm inc", "sentiment": "negative"}, {"name": "fda", "sentiment": "negative"}, {"name": "fda approval of apadaz", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 23 (Reuters) - Kempharm Inc:\n* KEMPHARM SAYS U.S. FDA APPROVED NDA FOR APADAZ FOR SHORT-TERM MANAGEMENT OF ACUTE PAIN SEVERE ENOUGH TO REQUIRE OPIOID ANALGESIC\n* KEMPHARM SAYS U.S. DRUG ENFORCEMENT ADMINISTRATION INDICATED INTENT TO SCHEDULE APADAZ AS A C-II PRODUCT\n* KEMPHARM ANNOUNCES FDA APPROVAL OF APADAZ (BENZHYDROCODONE AND ACETAMINOPHEN) FOR SHORT-TERM MANAGEMENT OF ACUTE PAIN Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-24T03:05:00.000+02:00", "crawled": "2018-02-23T21:43:47.025+02:00", "highlightTitle": ""}